BioCentury | Jul 8, 2019
Company News

July 8 Company Quick Takes: Merck, Skyhawk in discovery deal; plus MorphoSys, BioMarin, Roche-Spark and Hanmi

...acquired an exclusive option to develop and commercialize QC inhibitors for cancer from neurology company Vivoryon Therapeutics AG...
...€15 million ($16.9 million) in a planned funding round for Vivoryon this year. Vivoryon (formerly Probiodrug...
...Co. Inc. MorphoSys AG Skyhawk Therapeutics Inc. Spark Therapeutics Inc. Vivoryon Therapeutics N.V. Roche CD47 Factor VIII Signal regulatory protein alpha (SIRPA) (CD172a) (SHPS-1) Vivoryon Therapeutics AG...
BioCentury | Apr 23, 2018
Company News

Management tracks: Probiodrug, Alder

...Neurology company Probiodrug AG (Euronext:PBD) said Chairman and CEO Konrad Glund will retire, effective April 30...
...He will be succeeded by Ulrich Dauer, who was CEO of Ventaleon GmbH (Gemünden, Germany). Probiodrug...
BioCentury | Feb 2, 2018
Finance

Private ambition

...has only invested in two other private companies in the past decade: Alzheimer’s disease company Probiodrug...
BioCentury | Nov 3, 2017
Clinical News

Probiodrug planning Phase IIb trials of PQ912 for early AD

...Next year, Probiodrug AG (Euronext:PBD) plans to start a European Phase IIb trial of glutaminyl cyclase...
...in SAPHIR received twice-daily 800 mg oral PQ912 or placebo for 12 weeks. In June, Probiodrug...
...Trials on Alzheimer’s Disease meeting in Boston on Nov. 1 (see BioCentury, July 21 ). Probiodrug...
BioCentury | Jul 31, 2017
Distillery Therapeutics

Neurology

...Next steps include developing and testing additional QC inhibitors in models of AD and neuroinflammation. Probiodrug...
BioCentury | Jul 21, 2017
Product Development

Surrogate start

...Phase II results for Probiodrug AG ’s Alzheimer’s disease candidate point to potential surrogate markers for...
...moving into large, lengthy and expensive Phase III trials. This obviously has not panned out. Probiodrug’s...
...increase has been linked to cognitive decline in natural history studies in AD. “Companies like Probiodrug...
BioCentury | Jun 16, 2017
Clinical News

Probiodrug reports Phase IIa data for glutaminyl cyclase inhibitor in early AD

...glycoprotein-39 ( CHI3L1 ; YKL40), a biomarker of inflammation, vs. placebo (p=0.1 and p=0.07, respectively). Probiodrug...
...Mini-Mental State Examination (MMSE) score of 25.5 points. PQ912 is a glutaminyl cyclase (QC) inhibitor. Probiodrug...
BioCentury | Mar 4, 2017
Product Development

Diagnosing AD trials

...biomarkers in specimens obtained from clinical trials that might eventually be turned into companion diagnostics. Probiodrug...
...Rochester, Minn. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. National Institutes for Health, Bethesda, Md. Probiodrug...
BioCentury | Oct 10, 2016
Financial News

Probiodrug completes private placement

Probiodrug AG (Euronext:PBD), Halle/Saale, Germany Business: Neurology Date completed: 2016-10-06 Type: Private placement Raised: EUR14.9 million ($16.7 million) Shares: 744,248 Price: EUR20 Shares after offering: 8.2 million Investor: Institutional investors Underwriters: Kempen & Co.; Bank...
BioCentury | Aug 15, 2016
Company News

Management tracks

...Aurentz as EVP and CBO. He was CBO at Epirus Biopharmaceuticals Inc. (Pink:EPRSQ). CNS company Probiodrug...
Items per page:
1 - 10 of 75
BioCentury | Jul 8, 2019
Company News

July 8 Company Quick Takes: Merck, Skyhawk in discovery deal; plus MorphoSys, BioMarin, Roche-Spark and Hanmi

...acquired an exclusive option to develop and commercialize QC inhibitors for cancer from neurology company Vivoryon Therapeutics AG...
...€15 million ($16.9 million) in a planned funding round for Vivoryon this year. Vivoryon (formerly Probiodrug...
...Co. Inc. MorphoSys AG Skyhawk Therapeutics Inc. Spark Therapeutics Inc. Vivoryon Therapeutics N.V. Roche CD47 Factor VIII Signal regulatory protein alpha (SIRPA) (CD172a) (SHPS-1) Vivoryon Therapeutics AG...
BioCentury | Apr 23, 2018
Company News

Management tracks: Probiodrug, Alder

...Neurology company Probiodrug AG (Euronext:PBD) said Chairman and CEO Konrad Glund will retire, effective April 30...
...He will be succeeded by Ulrich Dauer, who was CEO of Ventaleon GmbH (Gemünden, Germany). Probiodrug...
BioCentury | Feb 2, 2018
Finance

Private ambition

...has only invested in two other private companies in the past decade: Alzheimer’s disease company Probiodrug...
BioCentury | Nov 3, 2017
Clinical News

Probiodrug planning Phase IIb trials of PQ912 for early AD

...Next year, Probiodrug AG (Euronext:PBD) plans to start a European Phase IIb trial of glutaminyl cyclase...
...in SAPHIR received twice-daily 800 mg oral PQ912 or placebo for 12 weeks. In June, Probiodrug...
...Trials on Alzheimer’s Disease meeting in Boston on Nov. 1 (see BioCentury, July 21 ). Probiodrug...
BioCentury | Jul 31, 2017
Distillery Therapeutics

Neurology

...Next steps include developing and testing additional QC inhibitors in models of AD and neuroinflammation. Probiodrug...
BioCentury | Jul 21, 2017
Product Development

Surrogate start

...Phase II results for Probiodrug AG ’s Alzheimer’s disease candidate point to potential surrogate markers for...
...moving into large, lengthy and expensive Phase III trials. This obviously has not panned out. Probiodrug’s...
...increase has been linked to cognitive decline in natural history studies in AD. “Companies like Probiodrug...
BioCentury | Jun 16, 2017
Clinical News

Probiodrug reports Phase IIa data for glutaminyl cyclase inhibitor in early AD

...glycoprotein-39 ( CHI3L1 ; YKL40), a biomarker of inflammation, vs. placebo (p=0.1 and p=0.07, respectively). Probiodrug...
...Mini-Mental State Examination (MMSE) score of 25.5 points. PQ912 is a glutaminyl cyclase (QC) inhibitor. Probiodrug...
BioCentury | Mar 4, 2017
Product Development

Diagnosing AD trials

...biomarkers in specimens obtained from clinical trials that might eventually be turned into companion diagnostics. Probiodrug...
...Rochester, Minn. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. National Institutes for Health, Bethesda, Md. Probiodrug...
BioCentury | Oct 10, 2016
Financial News

Probiodrug completes private placement

Probiodrug AG (Euronext:PBD), Halle/Saale, Germany Business: Neurology Date completed: 2016-10-06 Type: Private placement Raised: EUR14.9 million ($16.7 million) Shares: 744,248 Price: EUR20 Shares after offering: 8.2 million Investor: Institutional investors Underwriters: Kempen & Co.; Bank...
BioCentury | Aug 15, 2016
Company News

Management tracks

...Aurentz as EVP and CBO. He was CBO at Epirus Biopharmaceuticals Inc. (Pink:EPRSQ). CNS company Probiodrug...
Items per page:
1 - 10 of 75